Cat. No.: DIA-0243117
Product Information | |
---|---|
CAS No. | 192050-59-2 |
Synonyms | LY333531 mesylate |
Formula | C29H32N4O6S |
Molecular Weight | 564.65 |
SMILES | O=C1NC(C(C2=CN(C3=CC=CC=C32)CCO[C@H](CN(C)C)CC4)=C1C5=CN4C6=CC=CC=C56)=O.CS(=O)(O)=O |
Target | PKC |
Product Description | Ruboxistaurin (LY333531) mesylate is an orally active, selective and ATP competitive PKCβ inhibitor with IC50 values of 4.7 and 5.9 nM for PKCβI and PKCβII, respectively. Ruboxistaurin mesylate can be used for the research of eye disorders, heart failure and diabetes. |
Format & Storage | |
---|---|
Format | Solid |
Color | Orange to red |
Purity | 99.87% |
Shipping | Room temperature in the continental U.S. Other areas may vary. |
Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.